GRIDIRON PUBLIC AFFAIRS, LLC

Lobbying for AGIOS PHARMACEUTICALS · Biotech/biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $10,000.00 income · posted Jul 16, 2026

Bills named in this filing 2

HR 5187
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing ca…
HR 5094
Protect Patients from Costly Care Act

Lobbying activity 1

Health Issues

Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.